TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in the Immune Cellular Signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in total energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in quality of life measured by FACT-Cx
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of attacks with aura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Range of motion of the particular joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of other product-related/possibly related adverse events or serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the blood glucose curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute bioavailability of DA-1229 (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mass balance recovery (Ae, %Ae)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to pneumococcal polysaccharide vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinician Assessment of PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of severity of spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional connectivity on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resting state blood oxygenation level dependent (BOLD) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diffusion tensor imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse Events (AE) reporting
Endpoint domain: Adverse events/effects
Primary endpoint: TMAO metabolite concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of treatment interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic responses to glucose challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of study participants with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Measure of Perinatal Death, Maternal Death, or Maternal Severe Complications
Endpoint domain: Mortality/survival
Primary endpoint: T-PA release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Pre- to Post-treatment Scores of Chemical Peel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in H-Reflex Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Mean log10 Titer in Serum AGS-v PLUS Specific Immunoglobulin Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean log10 Concentration in Th1 and Th2 Cytokine Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 90 days complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy between groups post-index procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Obstructive Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Global Impression-Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Clinical Global Impression-Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subsyndromal delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine toxicology for cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: occurrence of major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent Acute Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: safety of microsurgery human neural stem cells transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Herth Hope Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Primary Pharmacokinetic Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Average Myocardial Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge of increased risk in donor kidney transplants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 18F-FDG uptake in lymphomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load in plasma, genital tract, and gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latent viral reservoir (pro-viral DNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune effects (CD4/CD8 immunophenotypes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti Mullerian Hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Utilization of NIR intraoperative imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Spontaneous Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Positive Pressure Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for subsequent endotracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with delayed bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Renal Function Assessed by Measured GFR (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Subjects Satisfied With Treatment in a Sub-group Utilizing More Than 2 IPG Ports at 365 Days Post-IPG Implantation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change of pain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of range of motion from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shoulder angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a First Episode of Virologically-confirmed COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced One or More Serious AE (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Fatal SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Comfort Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Sleep Habits
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Average of Male Health Sexual Questionnaire (MHSQ) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to middle ear effusion resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in Contracture to 5° or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: P50 Ratio Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Throughput (TP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical rating scale (0-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced STD morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduced risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utility and clinical relevance of FDG-PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of FDG-PET by documentation of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esthetic properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child anthropometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Dose (RD)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of LTCD8+CD25highFoxp3+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Incidence and Nature of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the insulin concentration curve (AUCins) 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin concentration (Cins).max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under curve (AUC) Glucose infusion rate (GIR) 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of combination pembrolizumab and cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Event-free survival (EFS) at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline of Trough FEV1 at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients With Next Adverse Clinical Outcome Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Best-Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrity of guidewire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tube Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression of chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EMT-TF mRNA levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Movement Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Path-to-Target Movement Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Selection Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum phosphorus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety data
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (T1/2, Cmax, Ctrough, 7d, tmax, volume of distribution, clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Serum uric acid response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of participants with adverse events within 24 hours of CT exam
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with adverse events within 30 days of CT exam
Endpoint domain: Adverse events/effects
Primary endpoint: Change in stride velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of HOXA in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final clinical diagnosis of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Male Hypogonadal Subjects With Average Plasma Total Testosterone Within the Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Engagement in high risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Serum level of blood proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of subsequent episodes of deliberate self harm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed to future episodes of deliberate self harm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Joint Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salt taste perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Ryge Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with DNR singing observation form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CAL-263
Endpoint domain: Adverse events/effects
Primary endpoint: Sun Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance-Approach time difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine NGAL/Cr value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to First Bowel Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Depressive Symptoms Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Responders achieving Moderate Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant success rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of satisfactory sexual encounters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Analyte in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of post-test results and counseling
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of Participants Who Develop Major Bleeding Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of F2-isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Female Sexual Function Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Index of Erectile Function (IIEF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Free Moxifloxacin Fecal Concentration-time Curve (AUC D1-D16)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway Pressure Generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: accuracy of severe whitening for diagnosing gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: accuracy of delayed fading for diagnosing gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first measurement of plasma vancomycin concentration between 20 and 25 mg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intended concentration (15-20 mg/L) and adherence to the dosing protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in décolletage crepiness and wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of satisfactory vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Primary Total Knee Replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Central hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of Muscle Invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PUQE Score for Assessment of Severity in Hyperemesis Gravidarum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: VAS Score for Assessment of Severity in Hyperemesis Gravidarum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sensitivity and specificity for HCV RNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of HCV viral load level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cell-free donor DNA to recipient DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes